Novel vaccines that can effectively target both coronaviruses and influenza viruses would be desirable to counteract the significant health burden these respiratory pathogens pose.
Sunshine Biopharma Inc. announced it has developed an orally active protease inhibitor that showed dose-dependent antiviral activity in mice infected with SARS-CoV-2.
The Agency for Science Technology & Research (A*STAR) Bioprocessing Technology Institute has patented 3C-like proteinase (3CLpro; Mpro; nsp5) (coronavirus) inhibitors.
One of the challenges associated with COVID-19 has been an increase of secondary infections, including fungal infections. These coinfections can hinder treatment efficacy and increase illness severity.
The COVID-19 pandemic pushed the urgency for effective antiviral drugs against coronaviruses. Researchers from Europe conducted machine learning and in vitro validation experiments for the identification of potential antiviral drugs effective against coronaviruses.
Tohoku University has disclosed 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections and inflammatory disorders.
